In this training, Alison Esquea and Ryne Carney address the potential impacts of the Inflation Reduction Act on Medicare policy and spending, providing a comprehensive overview of the legislative and regulatory landscape as it pertains to healthcare professionals.
- Medicare Advantage (MA) is estimated to be 22% more expensive than traditional Medicare, a significant increase from the previous year's estimate of 6%.
- The Inflation Reduction Act introduces significant changes to prescription drug policy, including drug price negotiation, inflationary rebates, and a redesigned Part D.
- The looming insolvency of the Medicare Hospital Insurance Trust Fund is expected by 2031, potentially impacting Medicare's ability to cover costs.